Reuven Ron

Biomas Ltd. was established in year 2000 to commercialize proprietary intellectual property (“IP”) related to unique Tellurium based drugs. BioMas’s drugs evidenced in both pre-clinical and/or in Phase II human clinical trials, the ability to treat : • Central Nervous System diseases (like Parkinson's Disease, Stroke, Epilepsy and more) • Dermatological diseases (like Human Papiloma Warts and Psoriasis) • Certain cancer related issues

Algen Biopharmaceuticals Inc. is a biopharmaceutical company established in November 2000, to develop and commercialize lead compounds, gene therapy methods and technologies from the laboratory of Prof. Alexander Levitzki at the Hebrew University of Jerusalem. Prof. Levitzki, who is a world renowned expert in cancer and a recipient of the Israel Prize and other important honors for his work in cancer research and in elaborating the mechanisms of communication between cells, serves as Chief Scientific Office

Responsible of commercialization projects, negotiation and raising funds. Business negotiations (both national and international) with more than 150 companies worldwide, such as: Teva, Intec Pharma, Nice, Medinol, Lucent Technologies, , Wyeth-Ayerst, Minolta, Bohringer Ingelheim, Rhone-Poulence Roner Inc., Novartias Pharma AG, Boston Scientific Inc etc. These negotiation includes license Agreements and establish start up companies.

Atox Bio is a biotechnology company planned to commercialize the novel platform technology in the field of cellular immunology developed by a scientific team at The Hebrew University-Hadassah Medical School headed by Professor Raymond Kaempfer. My involvement led to investment of $5.6M

Novia is working on pharmaceutical antioxidants that can pass into the brain to treat neuronal lesions; and it is testing its first lead compound, AD4, which will be used to treat central nervous system disorders such as Parkinson’s disease and Alzheimer's disease. My involvement led to investments of $2M.

Target-in: In the last few years a new approach for targeted therapy of human diseases was developed using cytotoxic molecules that were produced by gene fusion techniques. Due to strategies for which I was partly responsible, the company raised $1.5M.

SensoGene was established to develop and commercialize bioelectronic devices and products based on a wide technological platform developed by Prof Itamar Willner of The Institute of Chemistry, The Hebrew University of Jerusalem. Up to date SensoGene has raised over $2.5M.

Unresto This is a company in the field of cardio-vascular diseases in general and restenosis in particular. Up to date the company licensed its technology to an American company for the sum of $5M. As CEO, I was fully involved in this transaction.